Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 3
2007 3
2008 5
2009 3
2010 4
2011 6
2012 4
2013 6
2014 2
2015 4
2016 3
2017 4
2018 8
2019 5
2020 5
2021 5
2022 5
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Tunable polymeric micelles for taxane and corticosteroid co-delivery.
Shalmani AA, Wang A, Ahmed Z, Sheybanifard M, Mihyar R, Buhl EM, Pohl M, Hennink WE, Kiessling F, Metselaar JM, Shi Y, Lammers T, Peña Q. Shalmani AA, et al. Among authors: pohl m. Drug Deliv Transl Res. 2023 Nov 14. doi: 10.1007/s13346-023-01465-x. Online ahead of print. Drug Deliv Transl Res. 2023. PMID: 37962836
Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription.
Cameron DP, Grosser J, Ladigan S, Kuzin V, Iliopoulou E, Wiegard A, Benredjem H, Jackson K, Liffers ST, Lueong S, Cheung PF, Vangala D, Pohl M, Viebahn R, Teschendorf C, Wolters H, Usta S, Geng K, Kutter C, Arsenian-Henriksson M, Siveke JT, Tannapfel A, Schmiegel W, Hahn SA, Baranello L. Cameron DP, et al. Among authors: pohl m. Sci Adv. 2023 Oct 13;9(41):eadg5109. doi: 10.1126/sciadv.adg5109. Epub 2023 Oct 13. Sci Adv. 2023. PMID: 37831776 Free PMC article.
Lasting response by vertical inhibition with cetuximab and trametinib in KRAS-mutated colorectal cancer patient-derived xenografts.
Reissig TM, Ladigan-Badura S, Steinberg A, Maghnouj A, Li T, Verdoodt B, Liffers ST, Pohl M, Wolters H, Teschendorf C, Viebahn R, Admard J, Casadei N, Tannapfel A, Schmiegel W, Hahn SA, Vangala DB. Reissig TM, et al. Among authors: pohl m. Mol Oncol. 2023 Nov;17(11):2396-2414. doi: 10.1002/1878-0261.13510. Epub 2023 Sep 3. Mol Oncol. 2023. PMID: 37604687 Free PMC article.
Prevalence and potential relevance of hyperuricemia in pediatric kidney transplant recipients-a CERTAIN registry analysis.
Ehren R, Habbig S, Krupka K, Ernst A, Bald M, König S, Murer L, Özçakar ZB, Pohl M, Babenko N, Spartà G, Staude H, Dello Strologo L, Szabó AJ, Tönshoff B, Weber LT. Ehren R, et al. Among authors: pohl m. Pediatr Transplant. 2022 Jun;26(4):e14265. doi: 10.1111/petr.14265. Epub 2022 Mar 9. Pediatr Transplant. 2022. PMID: 35263498 Free article.
Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in AML/MDS patients.
Gerding WM, Tembrink M, Nilius-Eliliwi V, Mika T, Dimopoulos F, Ladigan-Badura S, Eckhardt M, Pohl M, Wünnenberg M, Farshi P, Reimer P, Schroers R, Nguyen HP, Vangala DB. Gerding WM, et al. Among authors: pohl m. Int J Cancer. 2022 Jun 15;150(12):1998-2011. doi: 10.1002/ijc.33942. Epub 2022 Feb 7. Int J Cancer. 2022. PMID: 35064925 Free article.
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.
Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Kirste S, Jacobasch L, Allgäuer M, Flentje M, Germer CT, Grützmann R, Hildebrandt G, Schwarzbach M, Bechstein WO, Sülberg H, Friede T, Gaedcke J, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group. Fokas E, et al. JAMA Oncol. 2022 Jan 1;8(1):e215445. doi: 10.1001/jamaoncol.2021.5445. Epub 2022 Jan 20. JAMA Oncol. 2022. PMID: 34792531 Free PMC article. Clinical Trial.
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
Vangala D, Ladigan S, Liffers ST, Noseir S, Maghnouj A, Götze TM, Verdoodt B, Klein-Scory S, Godfrey L, Zowada MK, Huerta M, Edelstein DL, de Villarreal JM, Marqués M, Kumbrink J, Jung A, Schiergens T, Werner J, Heinemann V, Stintzing S, Lindoerfer D, Mansmann U, Pohl M, Teschendorf C, Bernhardt C, Wolters H, Stern J, Usta S, Viebahn R, Admard J, Casadei N, Fröhling S, Ball CR, Siveke JT, Glimm H, Tannapfel A, Schmiegel W, Hahn SA. Vangala D, et al. Among authors: pohl m. Genome Med. 2021 Jul 16;13(1):116. doi: 10.1186/s13073-021-00926-7. Genome Med. 2021. PMID: 34271981 Free PMC article.
67 results